Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers.

Pascal Pujol (p-pujol@chu-montpellier.fr)
Department of Cancer Genetics, CHU Montpellier, Univ Montpellier
https://orcid.org/0000-0001-8315-4715

Kévin Yauy
SeqOne Genomics

Amandine Coffy
LMNT-AESIO Santé

Nicolas Dufrept-Frebourg
SeqOne Genomics

Sana Gabteni
Department of Cancer Genetics, CHU Montpellier, Univ Montpellier

Jean-Pierre Daurès
LMNT-AESIO Santé

Frédérique Penault-Llorca
Centre Jean Perrin

Frédéric Thomas
CREEC, UMR IRD 224-CNRS 5290

Kevin Hughes
Massachusetts General Hospital

Clare Turnbull
The Institute of Cancer Research

Virginie Galibert
Department of Cancer Genetics, CHU Montpellier, Univ Montpellier

Chloé Rideau
Department of Cancer Genetics, Chu Montpellier, Univ Montpellier

Laetitia Collet
Institut de Cancérologie des Hospices Civils de Lyon

Benoit You
Institut de Cancérologie des Hospices Civils e Lyon

David Geneviève
CHU Montpellier, Département de génétique médicale, Maladies rares et médecine personnalisée
Abstract

Background: PARP inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer (BC) who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA1/2) in both the metastatic and adjuvant setting. Therefore, we need to redefine the criteria of women and tumor phenotype that should be tested for gBRCA1/2.

Objective: We studied the relative distribution of gBRCA1 and gBRCA2 in unselected populations of women with BC and in unaffected individuals. We also analyzed the proportion of estrogen receptor (ER)-positive (ER+) tumors in unselected BC patients with gBRCA1/2.

Design: We performed a meta-analysis of studies of unselected BC that analyzed the relative contribution of gBRCA1 versus gBRCA2 and ER+ tumors among gBRCA1/2 carriers. We then performed a meta-analysis of gBRCA1/2 carriage in unaffected individuals, from genome-wide population studies, the gnomAD databank, and case–control studies.

Results: The BRCA2 gene was involved in 54% of BC in unselected patients with gBRCA1/2 (n=108,699) and 59% of unaffected individuals (n=238,973) as compared with 38% of gBRCA1/2 family cohorts (n=29,700). The meta-analysis showed that 1.66% (95% CI 1.08-2.54) and 1.71% (95% CI 1.33-2.2) of unselected BC patients carried a gBRCA1 and gBRCA2, respectively. In unaffected individuals, the frequency of heterozygosity for gBRCA1 and gBRCA2 was estimated at 1/434 and 1/288, respectively. Nearly 0.5% of unaffected individuals in the studied populations carried a gBRCA1/2. Overall, 58% of breast tumors occurring in women carrying a gBRCA1/2 were ER+ (n=86,870).

Conclusion: This meta-analysis showed that gBRCA2 carriage is predominant in unselected BC and in unaffected individuals. ER+ tumors among women with gBRCA1/2-related BC is predominant and has been underestimated. Because PARPi agents improve progression-free survival with ER+ gBRCA1/2 BC in both the adjuvant and metastatic setting, BC should be considered regardless of ER status for BRCA1/2 screening for therapeutic purposes.

Key Points

- This metaanalysis shows that in unselected breast cancer (BC) patients, 3.4% have a BRCA1 or BRCA2 germline pathogenic or likely pathogenic variant (gBRCA1/2), with gBRCA2 more frequent than gBRCA1.
- In unaffected individuals, gBRCA2 is more frequent than gBRCA1. The frequency of heterozygosity is estimated at 1/288 and 1/434, respectively.
- In unselected BC patients with gBRCA1/2, more than half of tumors are estrogen receptor-positive.

Introduction
Poly (ADP-ribose) polymerase inhibitor (PARPi) agents have been found effective for treating high-risk and metastatic breast cancer (BC) related to germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA1/2, 1-4). Therefore, we need to identify which BC patient and which tumor type could benefit from genetic screening.

In 70% of cases, BC related to gBRCA1 has an estrogen receptor negative (ER-) phenotype (5). Also, from the largest available families cohorts, among identified families with gBRCA1/2, gBRCA1 is the predominant molecular form, implicated in 62% of 29,700 identified families (6). Because of these features and other therapeutic options available for ER+ BC, screening for gBRCA1/2 in ER+ BC has not been prioritized, and most attention has been paid to genetic testing of ER- tumors for theragnostic purposes.

However, in patients with metastatic hormone-resistant ER+ BC, PARPi agents have increased both progression-free survival and quality of life as compared with chemotherapy (2-4; Fig. 1 supplement). In the adjuvant setting, progression-free survival was also improved in high-risk ER+ BC patients receiving olaparib (1). Therefore, the question of using PARPi agents in ER+ gBRCA1/2 BC is of major clinical relevance.

We performed a meta-analysis of available cohorts of unselected BC in the literature addressing the relative contribution of gBRCA1 and gBRCA2 and ER+ tumors in gBRCA1/2 patients overall. We then evaluated the prevalence of gBRCA1/2 carriage in unaffected individuals by a meta-analysis of genome-wide population studies, the gnomAD sequencing aggregation database and control groups of BC case-control studies.

**Patients And Methods**

The search strategy used variations and Boolean connectors of key terms and is given in supplementary data. We retained only unselected BC studies analyzing gBRCA1/2. To avoid potential selection bias, we thus excluded studies of BC women undergoing genetic testing under specific criteria such as family history, young age and screening for therapeutic trials with potential enrichment for triple-negative BC, studies of metastatic cancer, and studies of BC in specific ethnicities (e.g., French Canadian or Ashkenazi Jewish heritage). Studies of somatic mutation were retained only if gBRCA1/2 data were available.

We used Comprehensive Meta-Analysis software to estimate the pooled values of the parameters as well as their 95% confidence intervals (CIs). We estimated heterogeneity by using the Cochran Q test with the point estimate $I^2$. If heterogeneity was present ($Q$ statistic significant at 5%), we took it into account by using a random-effects model. Publication bias was visually estimated with funnel plots and quantified with the Egger test and the “trim-and-fill” method of Duval and Tweedie. Details on the meta-analyses are given in the supplement. gBRCA1/2 carriage was explored in the exome cohort (n=125,747) of gnomAD v2.1.1 (7). gBRCA1 and gBRCA2 were identified in the ClinVar database (8, August 2021 release).
Results

**gBRCA1 and gBRCA2 carriage in unselected BC patients**

Meta-analysis of unselected BC series showed that 3.4% of BC occurred in patients with gBRCA1/2 (n = 108,699, 95% CI 2.5-4.7, Figure 1a, supplement). gBRCA1 and gBRCA2 status accounted for 1.66% (95% CI 1.08-2.54) and 1.71% (95% CI 1.33-2.2) of BC (Figure 1b, 1c, supplement). Among BC patients with gBRCA1/2, 46% (n=1,496) carried a gBRCA1 and 54% (n=1,776) a gBRCA2 (supplement).

**Frequency of gBRCAm carriers in unaffected individuals**

We performed a meta-analysis of available data from genome-wide population studies and the gnomAD databank and for unaffected individuals of case–control studies of genetic testing in BC (9, 10). The frequency of gBRCA1 and gBRCA2 was 0.18% (95% CI 0.12-0.25) and 0.32% (95% CI 0.27-0.38), respectively (supplement). Carriage of gBRCA1/2 in the general population was 0.5% (95% CI 0.4-0.6) (Figure 2a, supplement). The frequency of heterozygous gBRCA1 and gBRCA2 was estimated at 1/434 and 1/288, respectively (supplement). The *BRCA2* gene accounted for 59% of total gBRCA1/2 carriers in the general population (Figure 2b, supplement).

**Frequency of ER+ tumors in unselected BC patients with gBRCAm**

The meta-analysis showed that 2.5% of patients with ER+ tumors (95% CI 1.5-4.1, Figure 3a) and 5.7% with ER- tumors (95% CI 5.1-6.2) carried a gBRCA1/2 (Figure 3b, supplement). Among gBRCA1 carriers, 38% (457/1218) had ER+ tumors, whereas among gBRCA2 carriers, 75% (1085/1453) had ER+ tumors. Overall, 58% (1542/2671) of breast tumors with gBRCA1/2 carriage were ER+ (n=86,870; Figure 3c; supplement).

Discussion

Our overall finding of a higher gBRCA2/gBRCA1 ratio in the BC population agrees with the most recent and largest studies of BRCA screening of unselected BC (9, 10). Because most BRCA1 cases of BC are ER- and most BRCA2 cases are ER+ (5), the frequency of ER+ tumors among the overall BC BRCA patients depends on the relative contribution of gBRCA2 incidence in unselected BC. In several published reports describing the frequency of gBRCA in BC series, the bias of selection on family criteria but also on age or triple-negative phenotype may have underestimated the frequency of gBRCA2.

Our finding of a predominant prevalence of gBRCA2 versus gBRCA1 in the general population also agrees with recent unselected population-genomic screening showing a higher-than-expected prevalence of...
gBRCA2 versus gBRCA1 in individuals of predominant European ancestry \(^{(11,12)}\). Further studies in other populations are needed to precise the prevalence of gBRCA1/2 by ancestry.

The higher incidence of gBRCA1 found in the largest international cohort of identified gBRCA1/2 carriers (CIMBA \(^{6}\)) could be due to lack of penetrance of BC with gBRCA2 carriage. However, the prospective study by Kuckenbacher et al.\(^{(13)}\) does not support this hypothesis because the cumulative lifetime risk is similar (cumulative BC risk to age 80 years: 72\% and 69\% for BRCA1 and BRCA2 carriers, respectively). More likely, because the occurrence of BC in gBRCA2 women is time-delayed as compared with gBRCA1 women, the older age of women at diagnosis could result in lack of testing for gBRCA2 carriage. Another potential explanation is that the higher incidence of ovarian cancer with gBRCA1 versus gBRCA2 carriage (cumulative risk to age 80 years is 44\% and 17\%, respectively) could also lead to more active BRCA testing in women with this criterion. Finally, the well-known triple-negative phenotype of BRCA1 tumors could also result in more referral for genetic testing for BRCA1 versus BRCA2 BC patients.

Our data strongly suggest that the frequency of gBRCA2 carriage and ER+ tumors among women with BC is underestimated because classical genetic testing criteria are often missing in gBRCA2 families. In a previous review of the literature, we found that 50\% of overall BRCA1/2 BC cases are missed when genetic testing criteria are used \(^{(14)}\). Accordingly, the study by Li et al. \(^{(15)}\) showed that a higher percentage of BRCA2 versus BRCA1 carriage (81\% vs 46\%) was missed by clinical screening. In the study of unselected BC cases by Beitsch et al.\(^{(16)}\), which excluded patients who had previously been tested, 86\% of the gBRCAm cases were gBRCA2.

This study shows that more than half of BC cases occurring in women with gBRCA1/2 are in fact ER+. It also shows that the frequency of gBRCA2 carriage is higher than expected in both unselected BC patients and in the general population. Because of the important benefit of identifying gBRCA1/2 carriage for PARPi treatment and prevention, ER+ BC should be considered fully for BRCA screening.

**Declarations**

**Funding:**

This work was commissioned and supported by the French Society of Predictive and Personalized medicine an independent nonprofit learned society.

**Acknowledgements:**

The authors acknowledge the contribution of patient advocacy from “BRCA France” and “Sapins de noël des créateurs” associations. Dr. Pujol discloses attending Advisory Board Membership meetings for AstraZeneca, Pfizer, Roche, Novartis and Exact Science. Dr Hughes discloses honoraria from Hologic Inc, Myriad Genetics and CRA Health LLC.
References

1. Tutt ANJ, Garber JE, Kaufman B, et al (2021) Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine 384:2394–2405
2. Litton JK, Rugo HS, Ettl J, et al (2018) Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 379:753–763
3. (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377:1700
4. Diéras V, Han HS, Kaufman B, et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282
5. Mavaddat N, Barrowdale D, Andrulis IL, et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21:134–147
6. Rebbeck TR, Friebel TM, Friedman E, et al (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593–620
7. Landrum MJ, Lee JM, Benson M, et al (2018) ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 46:D1062–D1067
8. Karczewski KJ, Francioli LC, Tiao G, et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434–443
9. Hu C, Hart SN, Gnanaolivu R, et al (2021) A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 384:440–451
10. Breast Cancer Association Consortium, Dorling L, Carvalho S, et al (2021) Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med 384:428–439
11. Abul-Husn NS, Soper ER, Odgis JA, et al (2019) Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med 12:2
12. Manickam K, Buchanan AH, Schwartz MLB, et al (2018) Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Netw Open 1:e182140
13. Kuchenbaecker KB, Hopper JL, Barnes DR, et al (2017) Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317:2402–2416
14. Pujol P, Barberis M, Beer P, et al (2021) Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer 146:30–47
15. Li J, Wen WX, Eklund M, et al (2019) Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int J Cancer 144:1195–1204
16. Beitsch PD, Whitworth PW, Hughes K, et al (2019) Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J Clin Oncol 37:453–460
Figures

1a. gBRCA1/2

Meta-analysis of gBRCA1 and gBRCA2 in unselected breast cancer

2a. gBRCA1/2 carriers in unaffected individuals

2b. Comparison of gBRCA1 and gBRCA2 frequency in family cohort, unselected BC and unaffected individuals

Figure 1

Figure 2

Meta-analysis of gBRCA1 and gBRCA2 in unaffected individuals

Figure 3

Meta-analysis of gBRCA1 and gBRCA2 in unselected BC by ER status

3a. gBRCA1/2 carriers in ER+ unselected BC
